These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38536719)

  • 1. Evaluation of the impact of antibody fragments on aggregation of intact molecules via size exclusion chromatography coupled with native mass spectrometry.
    Xu J; Coughlin JE; Szyjka M; Jabary S; Saluja S; Sosic Z; Chen Y; Xu CF
    MAbs; 2024; 16(1):2334783. PubMed ID: 38536719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity.
    Knight MJ; Floret L; Patel N; O'Hara J; Rodriguez E
    MAbs; 2022; 14(1):2127172. PubMed ID: 36198003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the Increased Aggregation Propensity of a Light-Exposed IgG1 Monoclonal Antibody Using Hydrogen Exchange Mass Spectrometry, Biophysical Characterization, and Structural Analysis.
    Bommana R; Chai Q; Schöneich C; Weiss WF; Majumdar R
    J Pharm Sci; 2018 Jun; 107(6):1498-1511. PubMed ID: 29408480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of monoclonal antibody fragments cleaved at the complementarity determining region using orthogonal analytical methods.
    Li W; Yang B; Zhou D; Xu J; Li W; Suen WC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Mar; 1048():121-129. PubMed ID: 28242491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of monoclonal antibody dimers in a final formulated drug by separation techniques coupled to native mass spectrometry.
    Rouby G; Tran NT; Leblanc Y; Taverna M; Bihoreau N
    MAbs; 2020; 12(1):e1781743. PubMed ID: 32633190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural analysis of a therapeutic monoclonal antibody dimer by hydroxyl radical footprinting.
    Deperalta G; Alvarez M; Bechtel C; Dong K; McDonald R; Ling V
    MAbs; 2013; 5(1):86-101. PubMed ID: 23247543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics and Characterization of Non-enzymatic Fragmentation of Monoclonal Antibody Therapeutics.
    Ravuluri S; Bansal R; Chhabra N; Rathore AS
    Pharm Res; 2018 May; 35(7):142. PubMed ID: 29761239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.
    Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Volkin DB; Weis DD
    MAbs; 2015; 7(1):84-95. PubMed ID: 25524268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrogen exchange mass spectrometry reveals protein interfaces and distant dynamic coupling effects during the reversible self-association of an IgG1 monoclonal antibody.
    Arora J; Hickey JM; Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Weis DD; Volkin DB
    MAbs; 2015; 7(3):525-39. PubMed ID: 25875351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinctive Low-Resolution Structural Features of Dimers of Antibody-Drug Conjugates and Parent Antibody Determined by Small-Angle X-ray Scattering.
    Law-Hine D; Rudiuk S; Bonestebe A; Ienco R; Huille S; Tribet C
    Mol Pharm; 2019 Dec; 16(12):4902-4912. PubMed ID: 31618040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyphenation of size exclusion chromatography to native ion mobility mass spectrometry for the analytical characterization of therapeutic antibodies and related products.
    Ehkirch A; Hernandez-Alba O; Colas O; Beck A; Guillarme D; Cianférani S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jun; 1086():176-183. PubMed ID: 29684909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity.
    Arora J; Hu Y; Esfandiary R; Sathish HA; Bishop SM; Joshi SB; Middaugh CR; Volkin DB; Weis DD
    MAbs; 2016; 8(8):1561-1574. PubMed ID: 27560842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody.
    Bond MD; Panek ME; Zhang Z; Wang D; Mehndiratta P; Zhao H; Gunton K; Ni A; Nedved ML; Burman S; Volkin DB
    J Pharm Sci; 2010 Jun; 99(6):2582-97. PubMed ID: 20039394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Native SEC and Reversed-Phase LC-MS Reveal Impact of Fab Glycosylation of Anti-SARS-COV-2 Antibodies on Binding to the Receptor Binding Domain.
    Woodall DW; Thomson CA; Dillon TM; McAuley A; Green LB; Foltz IN; Bondarenko PV
    Anal Chem; 2023 Oct; 95(42):15477-15485. PubMed ID: 37812809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Native Reversible Self-Association of a Monoclonal Antibody Mediated by Fab-Fab Interaction.
    Gentiluomo L; Roessner D; Streicher W; Mahapatra S; Harris P; Frieß W
    J Pharm Sci; 2020 Jan; 109(1):443-451. PubMed ID: 31563513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of mAb dimers reveals predominant dimer forms common in therapeutic mAbs.
    Plath F; Ringler P; Graff-Meyer A; Stahlberg H; Lauer ME; Rufer AC; Graewert MA; Svergun D; Gellermann G; Finkler C; Stracke JO; Koulov A; Schnaible V
    MAbs; 2016 Jul; 8(5):928-40. PubMed ID: 27031922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Characterization of a Monoclonal Antibody Variant Species with a Clipping in the Complementarity Determining Region Isolated by Size Exclusion Chromatography Under Native Conditions.
    Atsumi Y; Sakurai N; Nishimura K; Yamazaki K; Wakamatsu K
    J Pharm Sci; 2021 Oct; 110(10):3367-3374. PubMed ID: 34089708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab Deruxtecan.
    Deslignière E; Diemer H; Erb S; Coliat P; Pivot X; Detappe A; Hernandez-Alba O; Cianférani S
    Front Biosci (Landmark Ed); 2022 Oct; 27(10):290. PubMed ID: 36336868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Size-exclusion chromatography-mass spectrometry with m-nitrobenzyl alcohol as post-column additive for direct characterization of size variants of monoclonal antibodies.
    Xu CF; Zang L; Weiskopf A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jun; 960():230-8. PubMed ID: 24835510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the Degradation Behaviors of a Therapeutic Monoclonal Antibody Associated with pH and Buffer Species.
    Zheng S; Qiu D; Adams M; Li J; Mantri RV; Gandhi R
    AAPS PharmSciTech; 2017 Jan; 18(1):42-48. PubMed ID: 26340951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.